Complete patient guide — dosing, side effects, cost, and everything in between.
Ozempic (semaglutide) is a once-weekly injectable medication manufactured by Novo Nordisk. It belongs to a class of drugs called GLP-1 receptor agonists (glucagon-like peptide-1). Ozempic is FDA-approved for the treatment of type 2 diabetes in adults.
While Ozempic is approved for diabetes — not weight loss — it has become widely prescribed off-label for weight management due to its significant effect on appetite and body weight. Its sister drug, Wegovy, contains the same active ingredient (semaglutide) but at a higher max dose and with an FDA approval specifically for obesity.
Semaglutide activates GLP-1 receptors in the brain's hypothalamus — the hunger control center — reducing the feeling of hunger and increasing feelings of fullness.
Ozempic delays gastric emptying, meaning food stays in your stomach longer. This extends feelings of fullness and reduces overall food intake — and is also the primary cause of nausea.
It stimulates insulin release when blood sugar is high and suppresses glucagon release. This improves blood sugar control without causing dangerous hypoglycemia on its own.
Unlike older diabetes drugs, Ozempic only stimulates insulin when blood glucose is elevated — making low blood sugar (hypoglycemia) uncommon unless combined with insulin or sulfonylureas.
Ozempic is started at a low dose to allow your body to adjust, then gradually increased. Injections are given once per week on the same day each week — in the abdomen, thigh, or upper arm.
Most side effects are gastrointestinal and occur during dose escalation. They typically improve within 4–8 weeks as your body adjusts.
| Scenario | Monthly Cost |
|---|---|
| List price (no discounts) | ~$935 |
| Commercial insurance (diabetes indication) | ~$25–$50 |
| Novo Nordisk savings card (commercially insured) | $0–$99/mo |
| Medicare Part D | ~$30–$80 |
| GoodRx discount (varies by pharmacy) | ~$800–$900 |
| Patient Assistance Program (low income) | $0 (if eligible) |
This is one of the most-searched questions about GLP-1 drugs. Here's the truth: they're the same drug (semaglutide) at different doses with different FDA approvals.
| Factor | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| FDA Approval | Type 2 Diabetes | Obesity / Weight Loss |
| Max Dose | 2.0 mg | 2.4 mg |
| Avg Weight Loss | ~15% | ~15% (slightly more at 2.4mg) |
| List Price | ~$935/mo | ~$1,349/mo |
| Insurance (diabetes) | ✅ Usually covered | ❌ Different approval, varies |
| Best For | Type 2 diabetics | Obesity without diabetes |
Mounjaro (tirzepatide) is a newer dual-action drug that targets both GLP-1 and GIP receptors. Head-to-head data from the SURMOUNT-5 trial shows tirzepatide produces significantly more weight loss than semaglutide.
| Factor | Ozempic | Mounjaro |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Avg Weight Loss | ~15% | ~20% |
| Heart Disease Data | ✅ Proven (SUSTAIN-6) | ⏳ Pending trials |
| Nausea Risk | Moderate | Moderate-High |
| List Price | ~$935/mo | ~$1,023/mo |
| Best For | Proven heart benefit, established drug | Maximum weight loss |
Most patients notice appetite reduction within the first 2–4 weeks. Significant weight loss (5%+) is typically seen at 12–16 weeks. Maximum weight loss usually occurs at 52–68 weeks on the maintenance dose.
Doctors can prescribe Ozempic off-label for weight loss, but insurance likely won't cover it for this purpose. Wegovy (same drug, different approval) is the FDA-approved option for obesity without diabetes. Ask your doctor which is right for your situation.
Most people regain a significant portion of lost weight within 1–2 years of stopping. Hunger and blood sugar typically return to pre-treatment levels. GLP-1 medications treat a chronic condition — stopping them is similar to stopping blood pressure medication.
No generic semaglutide exists. Compounded semaglutide was widely available during the FDA shortage period (2022–2025) but is now restricted since Ozempic was removed from the shortage list. Be cautious of websites still selling compounded versions — verify with FDA guidelines.
Alcohol isn't strictly prohibited, but many Ozempic users become more sensitive to alcohol's effects. It can worsen nausea, cause blood sugar fluctuations, and increase dehydration. Many patients find they naturally drink less while on GLP-1 medications.
Rapid weight loss from any cause can reduce muscle mass. Studies show about 25–40% of weight lost on semaglutide may be lean mass. Combat this with resistance training (3x/week) and high protein intake (at least 0.8g per pound of body weight daily).